CN103509004A - Dabigatran caffeic acid salt as well as preparation method and application thereof - Google Patents
Dabigatran caffeic acid salt as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN103509004A CN103509004A CN201210215168.5A CN201210215168A CN103509004A CN 103509004 A CN103509004 A CN 103509004A CN 201210215168 A CN201210215168 A CN 201210215168A CN 103509004 A CN103509004 A CN 103509004A
- Authority
- CN
- China
- Prior art keywords
- caffeiate
- dabigatran etcxilate
- solvate
- hydrate
- dabigatran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RJWRAYIIAQIXGG-UHFFFAOYSA-N CCC(CNC)N Chemical compound CCC(CNC)N RJWRAYIIAQIXGG-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a Dabigatran caffeic acid salt represented by the following general formula and hydrates and/or solvates of the Dabigatran caffeic acid salt. The Dabigatran caffeic acid salt is structurally represented by a formula (I), wherein n is 1, 2 or 3. The invention further provides preparation methods of the Dabigatran caffeic acid salt and the hydrates and/or solvates of the Dabigatran caffeic acid salt and applications of the Dabigatran caffeic acid salt and the hydrates and/or solvates of the Dabigatran caffeic acid salt in the prevention of medicaments for treating or preventing cardiovascular diseases.
Description
Technical field
The present invention relates to a kind of acid salt of dabigatran etcxilate, be specifically related to a kind of dabigatran etcxilate caffeiate and its preparation method and application.
Background technology
Dabigatran (Dabigatran) is a kind of anti-coagulant of innovation, and thin blood medicine of new generation, on pharmacosystematics, belongs to " direct thrombin inhibitor " (Direct Thrombin Inhibitors, DTI).At present medical circle studies confirm that the effect that " dabigatran " brought into play in multinomial clinical indication, it likely replace belong to old-fashioned thin blood medicine " warfarin " (warfarin), become in most of cases for anticoagulant choice drug.
" dabigatran " enters human body with the form oral administration of its premedicant " dabigatran etcxilate " (dabigatran etexilate)." dabigatran etcxilate " researched and developed by German Boehringer Ingelheim, and in 2008, in Europe listing, commodity were called " Pradaxa ", and Canadian commodity are called " Pradax ".The Hong Kong Chinese commodity of " Pradaxa " are by name, and " the hundred Chinese trade names that reach Sheng”，Er China's Mainland and Taiwan are just in application audit.At present, existing 75Ge countries and regions are ratified it and be take " Pradaxa " as trade(brand)name list marketing.FDA (Food and Drug Adminstration) (FDA) ratified dabigatran etcxilate (a kind of oral direct thrombin inhibitor) for non-valvular Patients With Atrial Fibrillation (AF), to reduce the risk of its generation palsy and general blood vessel embolism on September 20th, 2010.
Dabigatran etcxilate (DABIGATRAN ETEXILATE) is a kind of benzimidazoles compound of replacement, chemical name 3-[[[2-[[[4-[[[(hexyloxy) carbonyl] amino] formamino] phenyl] amino] methyl]-1-methyl isophthalic acid H-benzoglyoxaline-5-yl] carbonyl] (pyridine-2-yl) amino] ethyl propionate, its molecular structural formula is as follows:
Molecular formula: C
34h
41n
7o
5, molecular weight: 627.74.
The solubleness of dabigatran etcxilate in water is less, and under the impact of pharmaceutical excipient and preventing, it is not easy to stripping in pharmaceutical preparation, and the preparation of pharmaceutical preparation is subject to many limitations.In addition, the dabigatran etcxilate mesylate having gone on the market (referring to Chinese patent CN1675193A) has the defects such as less stable, bioavailability be low, therefore need to find the compound that is more suitable for medicinal dabigatran etcxilate, to meet the demand of market and relative disease preventing and controlling.
Summary of the invention
Therefore, the object of the invention is to overcome the defect such as poor stability, the bioavailability of dabigatran etcxilate and existing compound thereof be low, a kind of stability is better, water-soluble more greatly, bioavailability is higher dabigatran etcxilate caffeiate and hydrate and/or solvate are provided, and their preparation method and application.
For achieving the above object, the invention discloses following technology contents:
Dabigatran etcxilate caffeiate, its hydrate and/or solvate that a kind of general formula is following:
（I）
Wherein, n is 1,2 or 3.
Dabigatran etcxilate caffeiate of the present invention, its hydrate and/or solvate, is characterized in that, the water that contains 0.5 ~ 10 molecule in dabigatran etcxilate caffeiate's hydrate described in per molecule.
Dabigatran etcxilate caffeiate of the present invention, its hydrate and/or solvate, is characterized in that, the water that contains 0.5 ~ 2 molecule in dabigatran etcxilate caffeiate's hydrate described in per molecule.
Dabigatran etcxilate caffeiate of the present invention, its hydrate and/or solvate, it is characterized in that, described solvate is one or more in alcohol solvent compound, methanol solvate compound, acetone solvate, acetonitrile solvate, ethyl acetate solvent compound, tetrahydrofuran solvate and ether solvent compound.
Dabigatran etcxilate caffeiate of the present invention, its hydrate and/or solvate, is characterized in that, in described hydrate, more than dabigatran etcxilate caffeiate accounts for 95 wt%.
The present invention further discloses the preparation method of dabigatran etcxilate caffeiate, its hydrate and/or solvate, it is characterized in that, the method comprises: dabigatran etcxilate and caffeiate are mixed to salify crystallization in water or the first organic solvent, after washing after filtration,, being dried, make water or the second organic solvent carry out recrystallization, make described dabigatran etcxilate caffeiate, its hydrate or solvate; Described dabigatran etcxilate and described caffeinic mol ratio are 98%.
Method of the present invention, wherein said mixing salify carries out to the reflux temperature of water or the first organic solvent at 0 ℃, at 0 ~ 30 ℃, carries out; Described dabigatran etcxilate and described caffeinic mol ratio are 3:1 ~ 1:3; Described the first organic solvent and the second organic solvent are identical or different, are selected from ethanol, methyl alcohol, propyl alcohol, Virahol, butanols, ethyl formate, ethyl acetate, isopropyl acetate, butylacetate, ether, isopropyl ether, n-butyl ether, glycol dimethyl ether, methyl tert-butyl ether, tetrahydrofuran (THF), sherwood oil, acetonitrile, methylene dichloride, trichloromethane, normal hexane, hexanaphthene, acetone, butanone, pentanone, toluene, N,N-DIMETHYLACETAMIDE or dimethylbenzene.
The present invention further discloses a kind of pharmaceutical composition, this pharmaceutical composition comprises dabigatran etcxilate caffeiate, its hydrate and/or solvate and pharmaceutically acceptable auxiliary material; In described pharmaceutical composition, the weight ratio of dabigatran etcxilate caffeiate and described pharmaceutically acceptable auxiliary material is 1:1 ~ 5.Preferred weight ratio is 1:1 ~ 2.
Pharmaceutical composition of the present invention is tablet, hard capsule, soft capsule, pill, granule, pellet or oral fluid agent; In described pharmaceutical composition, dabigatran etcxilate caffeiate and described pharmaceutically acceptable auxiliary material.
The present invention further discloses dabigatran etcxilate caffeiate, its hydrate and/or solvate in the application for the preparation of in treatment or the medicine of preventing cardiovascular disease, be particularly used for the treatment of or preventing the application in the medicine of phlebothrombosis or acute coronary syndrome.
Term as used herein " solvate ", refers to the crystallized form that comprises one or more organic solvent molecules in periodicity three-dimensional arrangement.
The phrase " pharmaceutically acceptable " using herein, refers in the scope of rational medicine judgement and is applicable to contact with the tissue of the mankind or animal compound, material, composition and/or the formulation that there is no excessive toxicity, pungency, anaphylaxis or other problem or complication simultaneously and have rational benefit/risk ratio.
According to dabigatran etcxilate caffeiate of the present invention, its hydrate and/or solvate, wherein, in dabigatran etcxilate caffeiate's hydrate, can contain the water of 0.5 ~ 10 molecule described in per molecule, can be preferably the water that contains 0.5 ~ 2 molecule.Described in per molecule, in dabigatran etcxilate caffeiate's solvate, can contain the solvent of 0.5 ~ 10 molecule, can be preferably the solvent that contains 0.5 ~ 2 molecule.
For example, dabigatran etcxilate caffeiate's of the present invention hydrate can be semihydrate, monohydrate, sesqui hydrate, dihydrate, two times of semihydrates, trihydrate, three times of semihydrates, tetrahydrate, four times of semihydrates, pentahydrate, five times of semihydrates, hexahydrate, six times of semihydrates, heptahydrate, seven times of semihydrates, eight hydrates, octuple semihydrate, nonahydrate, nine times of semihydrates or decahydrate.Again for example, the dabigatran etcxilate caffeiate's of per molecule solvate can contain the solvent of half molecule, 1 molecule, 1.5 molecules, 2 molecules, 2.5 molecules, 3 molecules, 3.5 molecules, 4 molecules, 4.5 molecules, 5 molecules, 5.5 molecules, 6 molecules, 6.5 molecules, 7 molecules, 7.5 molecules, 8 molecules, 8.5 molecules, 9 molecules, 9.5 molecules or 10 molecules.
Should illustrate, the above-mentioned dabigatran etcxilate caffeiate's of the present invention of enumerating hydrate or solvate, it is mainly a kind of existence form that dabigatran etcxilate caffeiate of the present invention produces in crystallization or purge process, the crystal water that it is contained or crystallization organic solvent normally can be controlled or remove, such as can crystal water or crystallization organic solvent being removed by modes such as heating calcination or calcinings.Therefore, dabigatran etcxilate caffeiate's of the present invention hydrate and solvate still belong to the content of technical scheme content of the present invention and scope of patent protection.
According to dabigatran etcxilate caffeiate of the present invention, its hydrate and/or solvate, wherein, described solvate can be one or more in alcohol solvent compound, methanol solvate compound, acetone solvate, acetonitrile solvate, ethyl acetate solvent compound, tetrahydrofuran solvate and ether solvent compound.
According to dabigatran etcxilate caffeiate of the present invention, its hydrate and/or solvate, wherein, in described hydrate, more than dabigatran etcxilate caffeiate can account for 95 wt%, more than can being preferably 98 wt%, can be more preferably more than 99 wt%.In described solvate, more than dabigatran etcxilate caffeiate can account for 95 wt%, more than can being preferably 98 wt%, can be more preferably more than 99 wt%.
The present invention also provides the method for preparing dabigatran etcxilate caffeiate of the present invention, its hydrate and/or solvate, the method can comprise: dabigatran etcxilate and coffic acid are mixed to salify crystallization in water or the first organic solvent, after washing after filtration,, being dried, make water or the second organic solvent carry out recrystallization, make described dabigatran etcxilate caffeiate, its hydrate or solvate.Those skilled in the art can be as required, by conventional means, as reduced Tc or steam except partial solvent etc., to accelerate the formation of crystallization.
The method according to this invention, wherein, the step of described mixing salify can be carried out at 0 ℃ to the reflux temperature of water or the first organic solvent, can be preferably at 0 ~ 30 ℃ and carry out.As preferably, the step of described crystallization can be carried out in room temperature or under lower than the condition of room temperature, can be preferably at 0 ~ 20 ℃ and carry out.Described the first organic solvent and the second organic solvent are identical or different, can be selected from ethanol, methyl alcohol, propyl alcohol, Virahol, butanols, ethyl formate, ethyl acetate, isopropyl acetate, butylacetate, ether, isopropyl ether, n-butyl ether, glycol dimethyl ether, methyl tert-butyl ether, tetrahydrofuran (THF), sherwood oil, acetonitrile, methylene dichloride, trichloromethane, normal hexane, hexanaphthene, acetone, butanone, pentanone, toluene, N,N-DIMETHYLACETAMIDE or dimethylbenzene.
The method according to this invention, wherein, described dabigatran etcxilate and described caffeinic mol ratio can be 10:1 ~ 1:10.This mol ratio can be preferably 3:1 ~ 1:3.
The present invention also provides a kind of pharmaceutical composition, this pharmaceutical composition comprises dabigatran etcxilate caffeiate of the present invention, its hydrate and/or solvate, or comprise dabigatran etcxilate caffeiate, its hydrate and/or the solvate making according to method of the present invention, and pharmaceutically acceptable auxiliary material.
Described pharmaceutical composition can comprise dabigatran etcxilate caffeiate of the present invention as active substance wherein, can also comprise the material that other has pharmaceutical active simultaneously, with the pharmaceutical composition that forms a kind of compound for combination therapy.
When dabigatran etcxilate caffeiate of the present invention is used for the treatment of as activeconstituents, generally directly do not give patient simple chemical, the form that is all conventionally the pharmaceutical composition that contains pharmaceutically acceptable auxiliary material occurs.Dabigatran etcxilate caffeiate of the present invention also can be by the administration of any appropriate, conventionally can be oral or parenteral route, so, the pharmaceutically acceptable auxiliary material that those skilled in the art also can select pharmaceutical composition to comprise according to required form of medication.
Be to be understood that, according to method well known in the art, pharmaceutically acceptable auxiliary material can be matrix or the auxiliary material that keeps pharmaceutical dosage form, conventionally according to different medicaments, select or be used in combination, optionally comprise vehicle, for example one or more in Microcrystalline Cellulose, lactose, pregelatinized Starch, starch, dextrin, calcium phosphate, sucrose, dextran, N.F,USP MANNITOL, sorbyl alcohol, glucose, fructose, water, polyoxyethylene glycol, propylene glycol, glycerine, cyclodextrin, cyclodextrin derivative etc.; Can also comprise tackiness agent, for example one or more in polyvidone (polyvinylpyrrolidone), methylcellulose gum, Walocel MT 20.000PV, HPMC, hydroxypropylcellulose, Natvosol, gelatin, guar gum, xanthan gum etc.; Also comprise lubricant, for example one or more in Magnesium Stearate, stearic acid, talcum powder, stearyl fumarate, Sodium Lauryl Sulphate BP/USP etc.; Can also comprise disintegrating agent, one or more in sodium starch glycolate, low-substituted hydroxypropyl cellulose, Xylo-Mucine, cross-linked polyvinylpyrrolidone, croscarmellose sodium, crosslinked carboxymethyl fecula sodium, pregelatinized Starch for example, etc.; Also comprise tensio-active agent, one or more of sodium lauryl sulphate, Tween-80 for example, etc.; Can also comprise pH value conditioning agent or buffer reagent, one or more of phosphate buffered saline buffer, citric acid, Trisodium Citrate, acetate buffer, dilute hydrochloric acid, sodium carbonate, sodium hydroxide for example, etc.; Can also comprise sanitas, one or more in Sodium Benzoate, potassium sorbate, methyl p-hydroxybenzoate, propylparaben for example, etc.; Can also comprise stablizer and oxidation inhibitor, one or more in Calcium Disodium Edetate, S-WAT, vitamins C for example, etc.; Can also comprise taste conditioning agent, one or more in maltose alcohol, fructose, sucrose, soluble saccharin, orange essence, strawberry flavour for example, etc.; Can also comprise in addition additive other routines, appropriate.
In addition,, when pharmaceutical dosage form is tablet or capsule, pharmaceutically acceptable auxiliary material can also comprise film dressing.For the material of film dressing, comprise applicable Drug coating, for example HPMC, Natvosol, hydroxypropylcellulose, hydroxypropyl methylcellulose phthalate, etc.; Can also comprise softening agent, for example polyoxyethylene glycol, triethyl citrate, etc.; Also comprise suitable solubilizing agent, as Tween-80; Can also comprise suitable pigment, as titanium dioxide, various ferric oxide, pink pigment, etc.
According to pharmaceutical composition of the present invention, described pharmaceutical composition can be tablet, hard capsule, soft capsule, pill, granule, pellet or oral fluid agent.
Pharmaceutical composition of the present invention can be prepared as acceptable any pharmaceutical dosage form in pharmaceutics as required, as oral preparations, injection formulations, parenteral liquid preparation, etc.; As oral tablet, capsule, granule, oral solution, powder agent, pill, sublingual administration agent, etc.; And for example injection, comprises powder ampoule agent for injection and injection liquid, etc., the emulsion of parenteral eye drop, nasal drops, [Dan, Transdermal absorption for another example, etc.Also can be the formulation such as quick-release, slowly-releasing, controlled release of above various formulations, for example oral dispersible tablet, slow releasing tablet, chewable tablet, slow releasing capsule, enteric coated tablet, effervescent tablet, orally disintegrating tablet, Special-shaped sheet, effervescent granule, etc.Especially, by means known in the art preparation, be preferred for preparing tablet edible in pharmaceutics (comprising dispersible tablet, slow releasing tablet, chewable tablet, enteric coated tablet, orally disintegrating tablet, Special-shaped sheet), capsule (comprise that stomach is molten, enteric, slow releasing capsule), granule, oral solution, injection (comprising powder ampoule agent for injection and injection liquid) etc., to meet the various needs in clinical use.
According to pharmaceutical composition of the present invention, wherein, in described pharmaceutical composition, the weight ratio of described dabigatran etcxilate caffeiate and described pharmaceutically acceptable auxiliary material can be 1:1 ~ 5, can be preferably 1:1 ~ 2.The content of dabigatran etcxilate caffeiate in pharmaceutical composition can be 0.1 ~ 100 mg, can be for example 0.1mg, 0.5mg, 1mg, 1.1mg, 1.2mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg or 150 mg, etc..
The present invention also provides dabigatran etcxilate caffeiate of the present invention, its hydrate and/or solvate, or the dabigatran etcxilate caffeiate who makes according to method of the present invention, its hydrate and/or solvate, the application in the medicine for the preparation for the treatment of or preventing cardiovascular disease.Can be preferably the application in the medicine for the preparation for the treatment of or prevention phlebothrombosis or acute coronary syndrome.
Dabigatran etcxilate caffeiate provided by the present invention, its hydrate and/or solvate have higher liberation degree, and its water-soluble acquisition is greatly improved.This can make dissolution process rapider on the one hand, also can reduce on the other hand the amount of required aqueous solvent.In addition, dabigatran etcxilate caffeiate of the present invention and hydrate thereof and solvate also have higher stability and bioavailability.
When being prepared as pharmaceutically active substances or preparation, storage and application galenical, the improvement of above biochemical property is very important, this quality that can guarantee galenical is higher, and its high stability also makes the procedure of processing of post-processed simpler, has reduced production cost.And its high crystalline can be used such as analytical procedures such as X-ray diffractions the release of its hydrate or solvate is carried out to simple and clear analysis, to carry out appropriate selection.For the galenical of these factors during for the quality of active substance and for preparation, storage and administration, be all very important.In addition, because the activeconstituents in galenical is more stable, thereby can avoid complicated preparation work.
The operation of use physical-chemical, processes as galenics such as dry, screening, grinding and medicament figurations, comprises combination treatment, granulation, spray-drying, compressing tablet etc., can make active substance absorb or loss moisture.This is also subject to temperature in its environment of living in and the impact of relative humidity.Under the situation of some preparations of preparation, the relating operation that free-water can be introduced into in conjunction with water or process because of preparation together with vehicle adds water in handled material.Therefore,, under differing temps and relative humidity, pharmaceutically active substances can contact with free-water within quite long period.In the case, dabigatran etcxilate caffeiate of the present invention does not show measurable moisture absorption or loss, therefore this stability is conducive to the final stage of its chemical preparation, also the treatment stage of being conducive to the galenic of different dosage form, and its stable lasting validity is of value to patient equally.
Meanwhile, dabigatran etcxilate caffeiate of the present invention also has better solvability or compressibility, thereby is more suitable for being directly compressed into corresponding tablet formulation or capsule.
In addition, dabigatran etcxilate caffeiate of the present invention also has better chemical stability, owing to containing aliphatic amide structure in dabigatran ester molecular structure, easily oxidized, can increase the stability of dabigatran etcxilate after salify.This salt also may have advantages of avoiding or reduce other activeconstituents degraded.
With Compound Phase ratio well known in the prior art, described salt also has more effectively, toxicity is lower, action time is longer, field of activity is wider, effect is higher, side effect still less, the advantage or other the useful pharmacological property that more easily absorb.
Accompanying drawing explanation:
Fig. 1 is dabigatran etcxilate caffeiate structural formula.
Embodiment
Below by specific embodiment, further illustrate the present invention, still, should be understood to, these embodiment are only used for the use specifically describing more in detail, and should not be construed as for limiting in any form the present invention.
The present embodiment is for illustrating dabigatran etcxilate caffeiate's of the present invention preparation.
The coffic acid of the dabigatran etcxilate of 1.6 mmol and 1.6 mmol is joined in the dehydrated alcohol of 20 ml at 20 ℃, 6 hours salifies of mix and blend, then crystallization at 20 ℃, filter, the washing of use ethyl acetate, after drying, add ether to carry out recrystallization, obtain the dabigatran etcxilate caffeiate's of 0.310 g ether solvent compound.Record ESI-MS(electron spray ionisation-mass spectrum) (m/z): 845[M+H]
+.
Above-mentioned ether solvent compound is dried, obtains dabigatran etcxilate coffic acid 0.296 g of white solid, as calculated, in above-mentioned ether solvent compound, dabigatran etcxilate caffeiate's content is 95.4wt%.The ether that contains 0.5 molecule in this ether solvent compound of per molecule.
Above-mentioned dabigatran etcxilate caffeiate is measured:
ESI-MS(m/z): 808 [M+H]
+
1H NMR(DMAO-
d 6 ,400 MHz)δ: 0.84(t,
J=9.0 Hz, 3H,CH
3), 1.09(t,
J=8.4 Hz, 3H,CH
3), 1.28-1.32(m, 6H,CH
2CH
2CH
2), 1.55-1.60(m, 2H, CH
2), 2.41-2.48(m, 2H,CH
2) ,3.76(s, 3H,CH
3), 3.94-4.04(m, 4H,2CH
2), 4.20(t,
J=14.4 Hz, 2H, CH
2),4.60(d,
J=5.6 Hz, 2H,CH
2), 6.76(d,
J=8.8 Hz, 2H,ArH), 6.87(d,
J=7.6 Hz, 1H,ArH), 7.01-7.16(m, 6H,ArH), 7.38(d,
J=8.6 Hz, 1H,ArH), 7.46(s, 1H,ArH), 7.51(dt,
J=10.4 Hz,
J=1.6 Hz,1H,ArH), 7.75(d,
J=8.6 Hz, 2H,ArH), 8.37(d,
J=4.0 Hz, 1H,ArH),9.31(br, 2H,NH
2)。
Ultimate analysis:
C
34H
41N
7O
5（627.74）·1/nC
4H
6O
5
Discovery value: C 63.93 N 12.14 H 6.11 O 17.82
Calculate: n=1
Therefore prepared dabigatran etcxilate caffeiate's molecular structural formula is:
Embodiment 2
The present embodiment is for illustrating dabigatran etcxilate caffeiate's of the present invention preparation.
The coffic acid of the dabigatran etcxilate of 3.2 mmol and 1.6 mmol is joined in 20 ml water at 30 ℃, 6 hours salifies of mix and blend, then crystallization at 30 ℃, filter, the washing of use ethyl acetate, after drying, add water to carry out recrystallization, obtain the dabigatran etcxilate caffeiate's of 0.450 g hydrate.Record ESI-MS (m/z): 736[M+H]
+.
Above-mentioned hydrate is dried, obtains dabigatran etcxilate caffeiate 0.439 g of white solid, as calculated, in above-mentioned hydrate, dabigatran etcxilate caffeiate's content is 97.5wt%.The water that contains 1 molecule in this hydrate of per molecule, i.e. monohydrate.
Above-mentioned dabigatran etcxilate caffeiate is measured:
ESI-MS(m/z): 718[M+H]
+
1H NMR(DMAO-
d 6 ,400 MHz)δ: 0.84(t,
J=9.0 Hz, 3H,CH
3), 1.09(t,
J=8.4 Hz, 3H,CH
3), 1.28-1.32(m, 6H,CH
2CH
2CH
2), 1.55-1.60(m, 2H, CH
2), 2.88-2.92(m, 2H,CH
2),3.76(s, 3H,CH
3), 3.94-4.04(m, 4H,2CH
2), 4.20(t,
J=14.4 Hz, 2H, CH
2),4.60(d,
J=5.6 Hz, 2H,CH
2), 6.76(d,
J=8.8 Hz, 2H,ArH), 6.87(d,
J=7.6 Hz, 1H,ArH), 7.01-7.16(m, 4.5H,ArH), 7.38(d,
J=8.6 Hz, 1H,ArH), 7.46(s, 1H,ArH), 7.51(dt,
J=10.4 Hz,
J=1.6 Hz,1H,ArH), 7.75(d,
J=8.6 Hz, 2H,ArH), 8.37(d,
J=4.0 Hz, 1H,ArH),9.31(br, 2H,NH
2)。
Ultimate analysis:
C
34H
41N
7O
5（627.74）·1/nC
4H
6O
5
Discovery value: C 64.42 N 13.66 H 6.32 O 15.60
Calculate: n=2
Therefore prepared dabigatran etcxilate caffeiate's molecular structural formula is:
embodiment 3
The present embodiment is for illustrating dabigatran etcxilate caffeiate's of the present invention preparation.
The coffic acid of the dabigatran etcxilate of 4.8 mmol and 1.6 mmol is joined in 20 ml dehydrated alcohols at 0 ℃, 6 hours salifies of mix and blend, then crystallization at 0 ℃, filter, the washing of use ethyl acetate, after drying, add glycol dimethyl ether to carry out recrystallization, obtain dabigatran etcxilate caffeiate 0.420 g of white solid.
Above-mentioned dabigatran etcxilate caffeiate is measured:
ESI-MS(m/z): 688[M+H]
+
1H NMR(DMAO-
d 6 ,400 MHz)δ: 0.84(t,
J=9.0 Hz, 3H,CH
3), 1.09(t,
J=8.4 Hz, 3H,CH
3), 1.28-1.32(m, 6H,CH
2CH
2CH
2), 1.55-1.60(m, 2H, CH
2), 2.88-2.92(m, 2H,CH
2),3.76(s, 3H,CH
3), 3.94-4.04(m, 4H,2CH
2), 4.20(t,
J=14.4 Hz, 2H, CH
2),4.60(d,
J=5.6 Hz, 2H,CH
2), 6.76(d,
J=8.8 Hz, 2H,ArH), 6.87(d,
J=7.6 Hz, 1H,ArH), 7.01-7.16(m, 4H,ArH), 7.38(d,
J=8.6 Hz, 1H,ArH), 7.46(s, 1H,ArH), 7.51(dt,
J=10.4 Hz,
J=1.6 Hz,1H,ArH), 7.75(d,
J=8.6 Hz, 2H,ArH), 8.37(d,
J=4.0 Hz, 1H,ArH),9.31(br, 2H,NH
2)。
Ultimate analysis:
C
34H
41N
7O
5（627.74）·1/nC
4H
6O
5
Discovery value: C 64.61 N 14.26 H 6.40 O 14.73
Calculate: n=3
Therefore prepared dabigatran etcxilate caffeiate's molecular structural formula is:
Embodiment 4
The present embodiment is for illustrating dabigatran etcxilate caffeiate's of the present invention preparation.
The coffic acid of the dabigatran etcxilate of 1.6 mmol and 4.8 mmol is joined in 20 ml anhydrous methanols at 30 ℃, 6 hours salifies of mix and blend, then crystallization at 10 ℃, filter, the washing of use ether, after drying, add tetrahydrofuran (THF) to carry out recrystallization, obtain the dabigatran etcxilate caffeiate's of 0.350 g tetrahydrofuran solvate.Record its ESI-MS (m/z): 844[M+H]
+.
Above-mentioned tetrahydrofuran solvate is dried, obtains dabigatran etcxilate caffeiate 0.334 g of white solid, as calculated, in above-mentioned solvate, dabigatran etcxilate caffeiate's content is 95.6wt%.The tetrahydrofuran (THF) that contains 0.5 molecule in this tetrahydrofuran solvate of per molecule.
Above-mentioned dabigatran etcxilate caffeiate is measured:
ESI-MS(m/z): 808[M+H]
+。
Ultimate analysis:
C
34H
41N
7O
5（627.74）·1/nC
4H
6O
5
Discovery value: C 63.93 N 12.14 H 6.11 O 17.82
Calculate: n=1
Therefore prepared dabigatran etcxilate caffeiate's molecular structural formula is:
Embodiment 5
The present embodiment is for illustrating dabigatran etcxilate caffeiate's of the present invention preparation.
The coffic acid of the dabigatran etcxilate of 1.6 mmol and 3.2 mmol is joined to 20 ml acetone at 10 ℃, 6 hours salifies of mix and blend, then crystallization at 10 ℃, filter, the washing of use ether, after drying, add acetone to carry out recrystallization, obtain the dabigatran etcxilate caffeiate's of 0.460 g acetone solvate.Record its ESI-MS (m/z): 837[M+H]
+.
Above-mentioned acetone solvate is dried, obtains dabigatran etcxilate caffeiate 0.450 g of white solid, as calculated, in above-mentioned solvate, dabigatran etcxilate caffeiate's content is 96.0wt%.The acetone that contains 0.5 molecule in this methanol solvate compound of per molecule.
Above-mentioned dabigatran etcxilate caffeiate is measured:
ESI-MS(m/z): 808[M+H]
+。
Ultimate analysis:
C
34H
41N
7O
5（627.74）·1/nC
4H
6O
5
Discovery value: C 63.93 N 12.14 H 6.11 O 17.82
Calculate: n=1
Therefore prepared dabigatran etcxilate caffeiate's molecular structural formula is:
Embodiment 6
The present embodiment is for illustrating dabigatran etcxilate caffeiate's of the present invention preparation.
The coffic acid of the dabigatran etcxilate of 1.6 mmol and 8 mmol is joined in 20 ml trichloromethanes at 30 ℃, 6 hours salifies of mix and blend, then crystallization at 20 ℃, filter, the washing of use ether, after drying, add water to carry out recrystallization, obtain the dabigatran etcxilate caffeiate's of 0.440 g hydrate.Record its ESI-MS (m/z): 817[M+H]
+.
Above-mentioned hydrate is dried, obtains dabigatran etcxilate caffeiate salt 0.435 g of white solid, as calculated, in above-mentioned hydrate, dabigatran etcxilate caffeiate's content is 99 wt%.The water that contains 0.5 molecule in this hydrate of per molecule, i.e. semihydrate.
Above-mentioned dabigatran etcxilate caffeiate is measured:
ESI-MS(m/z): 808[M+H]
+。
Ultimate analysis:
C
34H
41N
7O
5（627.74）·1/nC
4H
6O
5
Discovery value: C 63.93 N 12.14 H 6.11 O 17.82
Calculate: n=1
Therefore prepared dabigatran etcxilate caffeiate's molecular structural formula is:
Embodiment 7
The present embodiment is for illustrating the preparation of dabigatran etcxilate caffeiate's of the present invention pharmaceutical composition
[0068]prescription: 1000
The dabigatran etcxilate caffeiate 75.0g of embodiment 1
Lactose 80.0g
Microcrystalline Cellulose 30.0g
Polyvinylpolypyrrolidone 4.0g
Hypromellose 2.0g
Magnesium Stearate is appropriate
Dabigatran etcxilate caffeiate is crossed to 80 mesh sieves, and auxiliary material is crossed 60 mesh sieves.By recipe quantity, take dabigatran etcxilate caffeiate, Microcrystalline Cellulose and lactose and fully mix, add 1 %(weight/volume) hypromellose aqueous solution, softwood processed, sieves, and wet granular processed is dry in 55 ℃.Polyvinylpolypyrrolidone and Magnesium Stearate are added in above-mentioned particle, measure intermediate content, compressing tablet, packing.
Embodiment 8
The present embodiment is for illustrating the preparation of dabigatran etcxilate caffeiate's of the present invention pharmaceutical composition
Prescription: 1000 capsules
The dabigatran etcxilate caffeiate 75.0g of embodiment 2
Lactose 60.0g
Pregelatinized Starch 30g
Microcrystalline Cellulose 20.0g
Carboxymethylstach sodium 4.0g
Magnesium Stearate is appropriate
Dabigatran etcxilate caffeiate is crossed to 80 mesh sieves, and auxiliary material is crossed 60 mesh sieves.By recipe quantity, take dabigatran etcxilate caffeiate, Microcrystalline Cellulose, pregelatinized Starch and lactose and fully mix, add 1%(weight/volume) hypromellose aqueous solution, softwood processed, sieves, and wet granular processed is dry in 55 ℃.Magnesium Stearate is added in above-mentioned particle, measures intermediate content, encapsulated, packing.
Embodiment 9
The present embodiment is for illustrating the preparation of dabigatran etcxilate caffeiate's of the present invention pharmaceutical composition
Prescription: 100 bags of particles
The dabigatran etcxilate caffeiate 11.0g of embodiment 3
Lactose 67.0g
N.F,USP MANNITOL 20.0g
Aspartame 0.05g
Essence 0.05g
2 % hypromelloses (pure water preparation) are appropriate
Dabigatran etcxilate caffeiate is crossed to 80 mesh sieves, and auxiliary material is crossed 60 mesh sieves.By recipe quantity, taking dabigatran etcxilate caffeiate, lactose, N.F,USP MANNITOL, aspartame, essence fully mixes, add again 2 %(weight/volume) hypromellose aqueous solution softwood processed, 16 mesh sieves are granulated, 55 ℃ dry, the whole grain of 14 mesh sieves, measure intermediate content and moisture, packing, makes 100 bags of granules altogether.
Embodiment 10
The present embodiment is for illustrating the preparation of dabigatran etcxilate caffeiate's of the present invention pharmaceutical composition
1000 chewable tablet of writing out a prescription
The dabigatran etcxilate caffeiate 75.0g of embodiment 4
N.F,USP MANNITOL 80.0g
Microcrystalline Cellulose 20.0 g
Lactose 50.0 g
Polyvidone 6.0 g
Aspartame 5.0 g
Essence 2.0g
Magnesium Stearate is appropriate
Dabigatran etcxilate caffeiate is crossed to 80 mesh sieves, and auxiliary material is crossed 60 mesh sieves.By recipe quantity, taking dabigatran etcxilate caffeiate, polyvidone, aspartame and essence first mixes, fully mix with N.F,USP MANNITOL, Microcrystalline Cellulose and lactose successively again, finally add Magnesium Stearate to mix, measure intermediate content, compressing tablet, packing.
Although the present invention has carried out description to a certain degree, significantly, do not departing under the condition of the spirit and scope of the present invention, can carry out the suitable variation of each condition.Be appreciated that and the invention is not restricted to described embodiment, and be attributed to the scope of claim, it comprises the replacement that is equal to of described each factor.
Claims (10)
1. dabigatran etcxilate caffeiate, its hydrate and/or the solvate that general formula is following:
Wherein, n is 1,2 or 3.
2. dabigatran etcxilate caffeiate claimed in claim 1, its hydrate and/or solvate, is characterized in that, the water that contains 0.5 ~ 10 molecule in dabigatran etcxilate caffeiate's hydrate described in per molecule.
3. dabigatran etcxilate caffeiate claimed in claim 1, its hydrate and/or solvate, is characterized in that, the water that contains 0.5 ~ 2 molecule in dabigatran etcxilate caffeiate's hydrate described in per molecule.
4. the dabigatran etcxilate caffeiate described in any one, its hydrate and/or solvate in claims 1 to 3, it is characterized in that, described solvate is one or more in alcohol solvent compound, methanol solvate compound, acetone solvate, acetonitrile solvate, ethyl acetate solvent compound, tetrahydrofuran solvate and ether solvent compound.
5. the dabigatran etcxilate caffeiate described in any one, its hydrate and/or solvate in claims 1 to 3, is characterized in that, in described hydrate, more than dabigatran etcxilate caffeiate accounts for 95 wt%.
6. the preparation method of the dabigatran etcxilate caffeiate described in any one, its hydrate and/or solvate in claims 1 to 3, it is characterized in that, the method comprises: dabigatran etcxilate and caffeiate are mixed to salify crystallization in water or the first organic solvent, after washing after filtration,, being dried, make water or the second organic solvent carry out recrystallization, make described dabigatran etcxilate caffeiate, its hydrate or solvate; Described dabigatran etcxilate and described caffeinic mol ratio are 98%.
7. method according to claim 5, is characterized in that, described mixing salify carries out to the reflux temperature of water or the first organic solvent at 0 ℃, at 0 ~ 30 ℃, carries out; Described dabigatran etcxilate and described caffeinic mol ratio are 3:1 ~ 1:3; Described the first organic solvent and the second organic solvent are identical or different, are selected from ethanol, methyl alcohol, propyl alcohol, Virahol, butanols, ethyl formate, ethyl acetate, isopropyl acetate, butylacetate, ether, isopropyl ether, n-butyl ether, glycol dimethyl ether, methyl tert-butyl ether, tetrahydrofuran (THF), sherwood oil, acetonitrile, methylene dichloride, trichloromethane, normal hexane, hexanaphthene, acetone, butanone, pentanone, toluene, N,N-DIMETHYLACETAMIDE or dimethylbenzene.
8. a pharmaceutical composition, is characterized in that, this pharmaceutical composition comprises the dabigatran etcxilate caffeiate described in any one, its hydrate and/or solvate and pharmaceutically acceptable auxiliary material in claims 1 to 3; In described pharmaceutical composition, the weight ratio of dabigatran etcxilate caffeiate and described pharmaceutically acceptable auxiliary material is 1:1 ~ 5.
9. pharmaceutical composition claimed in claim 8, is characterized in that, described pharmaceutical composition is tablet, hard capsule, soft capsule, pill, granule, pellet or oral fluid agent; In described pharmaceutical composition, the weight ratio of dabigatran etcxilate caffeiate and described pharmaceutically acceptable auxiliary material is 1:1 ~ 2.
10. the dabigatran etcxilate caffeiate described in claims 1 to 3 any one, its hydrate and/or solvate be in the application for the preparation of in treatment or the medicine of preventing cardiovascular disease, is particularly being used for the treatment of or preventing the application in the medicine of phlebothrombosis or acute coronary syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210215168.5A CN103509004A (en) | 2012-06-27 | 2012-06-27 | Dabigatran caffeic acid salt as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210215168.5A CN103509004A (en) | 2012-06-27 | 2012-06-27 | Dabigatran caffeic acid salt as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103509004A true CN103509004A (en) | 2014-01-15 |
Family
ID=49892484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210215168.5A Pending CN103509004A (en) | 2012-06-27 | 2012-06-27 | Dabigatran caffeic acid salt as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103509004A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105440017A (en) * | 2014-08-19 | 2016-03-30 | 天津药物研究院 | Dabigatran etexilate vanillate and preparation method and application thereof |
-
2012
- 2012-06-27 CN CN201210215168.5A patent/CN103509004A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105440017A (en) * | 2014-08-19 | 2016-03-30 | 天津药物研究院 | Dabigatran etexilate vanillate and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019268052B2 (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
| CN102633777B (en) | Dabigatran etexilate 2-ketoglutarate as well as preparation method and application thereof | |
| JP6574417B2 (en) | Formulation containing amorphous dapagliflozin | |
| CN102391250B (en) | Dabigatran compound and preparation method and medicinal composition thereof | |
| CN102791271B (en) | Method for improving dissolvability of anticoagulant | |
| CN103304539A (en) | Dabigatran etexilate malate, and preparation method and application thereof | |
| EP2033629A1 (en) | Solid pharmaceutical composition comprising valsartan | |
| CN107693515B (en) | Pharmaceutical composition containing alkalizer and eltrombopag and application thereof | |
| JP2010519200A (en) | Controlled release formulation containing cilostazol and method for producing the same | |
| KR20190015329A (en) | A pharmaceutical composition of a dapagliflozin co-crystal | |
| TWI784575B (en) | A compound pharmaceutical composition and preparation method thereof | |
| JP6141580B2 (en) | Pharmaceutical composition of ranolazine and dronedarone | |
| JP5805891B2 (en) | Tablets containing 5-hydroxy-1H-imidazole-4-carboxamide | |
| KR101823071B1 (en) | Process for preparing telmisartan-containing tablets | |
| CN103570679A (en) | Dabigatran etexilate gluconate, preparation method and application thereof | |
| JP5491040B2 (en) | Tablets containing acarbose | |
| CN105367551A (en) | Dabigatran etexilate glycolate, preparation method and applications thereof | |
| JPWO2020090970A1 (en) | Pharmaceutical composition containing an antitumor agent | |
| WO2019130277A1 (en) | Pharmaceutical formulations of azilsartan medoxomil | |
| CN103509004A (en) | Dabigatran caffeic acid salt as well as preparation method and application thereof | |
| CN103664880A (en) | Novel anticoagulation medicine and preparation method and application thereof | |
| CN103570680A (en) | Dabigatran etexilate levulinic acid salt, preparation method and application thereof | |
| CN105440017B (en) | Dabigatran etcxilate vanillate and its preparation method and application | |
| CN105348261A (en) | Dabigatran etexilate pyruvate, preparation method and applications thereof | |
| WO2020111089A1 (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140115 |